



<b>Study Title:</b>	Treatment trial for Non-Small Cell Lung Cancer
<b>Scientific Title:</b>	ECOG E6508 – Phase II Study of BLP25 Liposome Vaccine and Bevacizumab After Definitive Chemoradiotherapy in Patients With Newly Diagnosed, Unresectable Stage IIIA or IIIB Nonsquamous Cell Non-Small Cell Lung Cancer
<b>Department and/or Specialty:</b>	Oncology-Lung-NSCLC
<b>Investigator:</b>	Michael Thompson, MD, PhD
<b>Contact Information:</b>	Chanda Miller 262-928-5539
<p>Vaccines may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine therapy together with bevacizumab after chemotherapy and radiation therapy may kill more tumor cells.</p> <p>This phase ii trial is studying the side effects of giving BLP25 liposome vaccine together with bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA and stage IIIB non-small cell lung cancer that cannot be removed by surgery.</p>	

